πŸ‡ΊπŸ‡Έ FDA
Patent

US 11999773

Anti-BCMA chimeric antigen receptors

granted A61KA61K2039/505A61K2239/46

Quick answer

US patent 11999773 (Anti-BCMA chimeric antigen receptors) held by Cartesian Therapeutics, Inc. expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cartesian Therapeutics, Inc.
Grant date
Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K2239/46, A61K38/00, A61K39/3955